ANRS Prévenir: ANRS Prévenir: High Efficacy of Daily or On-Demand FTC/TDF PrEP Among Parisian MSM in Interim Analysis of Open-Label Prospective Cohort Study

March 6-10, 2021; Virtual
Both PrEP regimens were highly effective in preventing HIV infection in this open-label study.
Format: Microsoft PowerPoint (.ppt)
File Size: 232 KB
Released: March 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Expert selections of important HIV data from IDWeek 2021, including current and investigational ART, HIV PrEP, and metabolic outcomes of ART.

Eric S. Daar, MD Darcy Wooten, MD Released: October 19, 2021

Concise Clinical Care Options (CCO) presentation by Nicholas Chamberlain, MD, on investigational HIV PrEP strategies in various stages of development

Nicholas Chamberlain, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: October 15, 2021 Expired: October 14, 2022

Clinical Care Options (CCO) slides from Nicholas Chamberlain, MD, on investigational HIV PrEP strategies in various stages of development

Nicholas Chamberlain, MD Released: October 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue